Trazodone for Sleep: Dosing, Safety, and What to Expect

What Is Trazodone and Why Is It Used for Sleep?

Trazodone is a serotonin antagonist and reuptake inhibitor originally approved by the FDA in 1981 for major depressive disorder under the brand name Desyrel. At antidepressant doses (150 to 400 mg/day), it blocks the serotonin transporter and serotonin 5-HT2A receptors. At the lower doses used for insomnia (25 to 150 mg), the dominant pharmacological action shifts to H1 histamine receptor antagonism and alpha-1 adrenergic blockade, both of which produce sedation. [1]

This receptor profile makes low-dose trazodone functionally different from the drug you prescribe at antidepressant doses. The sedating effects appear at doses well below those needed for mood elevation, which is exactly why clinicians began using it off-label for sleep decades before the evidence base caught up. A 2014 national survey of outpatient prescribing found trazodone was the second most commonly prescribed medication for insomnia in the United States, behind only zolpidem, despite carrying no FDA indication for that use. [2]

The absence of DEA scheduling is a practical advantage. Unlike zolpidem (Schedule IV), zaleplon (Schedule IV), and eszopiclone (Schedule IV), trazodone carries no federal controlled-substance classification, which means prescribers face fewer regulatory barriers and patients face lower risk of physical dependence with long-term use. [3]

Standard Trazodone Dosing for Insomnia

The standard starting dose for insomnia is 50 mg taken orally 30 minutes before bedtime, with food or without. For patients who are elderly, medically fragile, or highly sensitive to sedating medications, starting at 25 mg reduces the risk of morning grogginess and orthostatic hypotension. [4]

After one to two weeks, if sleep remains inadequate and the patient tolerates the starting dose, the prescriber may increase to 75 mg or 100 mg per night. Most published protocols cap the off-label sleep dose at 150 mg. Going beyond 150 mg at bedtime provides diminishing sedation benefit while substantially increasing the risk of next-day sedation, orthostatic hypotension, and QTc prolongation. [5]

A 2017 double-blind, randomized, placebo-controlled trial (N=137) published in the journal Sleep compared trazodone 50 mg to placebo in adults with primary insomnia. At two weeks, trazodone increased total sleep time by 37 minutes (P<0.01) and reduced wake after sleep onset by 21 minutes (P<0.05) without significant next-day sedation at that dose. [6] The effect size was modest but clinically meaningful for a drug with no abuse potential.

Titration schedule used in most clinical protocols:

| Week | Dose | Notes | |------|------|-------| | 1, 2 | 25 to 50 mg | Assess tolerance, morning function | | 3, 4 | 75 mg | If partial response at lower dose | | 5, 6 | 100 mg | If still inadequate; monitor blood pressure | | 7+ | 150 mg max | Rarely needed; reassess diagnosis |

Food does not significantly alter trazodone's peak plasma concentration for sleep purposes, though taking it with a small snack may reduce nausea in sensitive patients. [1]

Maximum Recommended Dose for Sleep Versus Depression

Trazodone's dosing range differs substantially between its two main clinical uses, and conflating them creates patient confusion.

For insomnia, the off-label ceiling in published clinical guidance is generally 150 mg per night. The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline for chronic insomnia notes that trazodone has weak evidence quality for insomnia and sets no formal maximum, but the studies cited use doses between 25 mg and 150 mg. [7] Doses above 150 mg at bedtime move the drug into partial antidepressant territory and are rarely justified for insomnia alone.

For major depressive disorder, the FDA-approved dosing starts at 150 mg per day in divided doses and may be titrated to 400 mg per day in outpatients or 600 mg per day in hospitalized patients. [1] These ranges are not appropriate as sleep doses and should never be conflated.

Z-Drug Maximum Dosing: A Comparison Benchmark

Patients frequently ask how trazodone compares to the Z-drugs, a shorthand for the non-benzodiazepine GABA-A receptor agonists approved specifically for insomnia. The FDA-approved maximum doses for the three most prescribed Z-drugs are:

• Zolpidem (Ambien): 10 mg per night for men; 5 mg per night for women per the 2013 FDA label revision due to next-morning impairment data. [8]
• Eszopiclone (Lunesta): 3 mg per night maximum; the FDA reduced the starting dose recommendation to 1 mg in 2014 after identifying next-morning driving impairment at 3 mg. [9]
• Zaleplon (Sonata): 20 mg per night maximum; 10 mg standard starting dose. [10]

A 2019 meta-analysis in The BMJ (N=30 trials, 4,539 patients) found that Z-drugs modestly reduced sleep-onset latency (mean reduction 22 minutes) and increased total sleep time (mean increase 25 minutes) but were associated with a relative risk of adverse events of 1.73 compared to placebo, including next-day psychomotor impairment and dependency. [11] Trazodone does not carry the same dependency or psychomotor warning profile at sleep doses.

The 2023 American College of Physicians (ACP) guideline on chronic insomnia disorder recommended that clinicians use cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment before any pharmacological agent, including both trazodone and Z-drugs. When pharmacotherapy is needed, the guideline cited evidence for both classes but noted the superior long-term safety profile of non-scheduled agents. [12]

How Trazodone Affects Sleep Architecture

Trazodone's mechanism at sleep doses does more than induce unconsciousness. It changes the structure of sleep in ways that differ from both benzodiazepines and Z-drugs.

Polysomnographic data from a randomized crossover study (N=18 healthy adults) published in Psychopharmacology found that trazodone 100 mg at bedtime significantly increased slow-wave sleep (stage N3) time by a mean of 18 minutes versus placebo (P<0.05) and did not suppress REM sleep. [13] Benzodiazepines and Z-drugs generally suppress slow-wave sleep, which is considered the most restorative phase of the sleep cycle.

This slow-wave preservation is one reason some sleep medicine specialists consider trazodone preferable for patients with comorbid mood disorders or those recovering from alcohol use disorder, where sleep architecture is already disrupted. A 2020 review in Alcohol Research: Current Reviews noted that trazodone reduced alcohol relapse-related insomnia in early recovery without the abuse potential of benzodiazepines. [14]

Trazodone Dosing in Special Populations

Elderly patients. The 2023 Beers Criteria from the American Geriatrics Society lists trazodone as a drug to use with caution in adults aged 65 and older due to risk of orthostatic hypotension and falls. If used, starting at 25 mg and avoiding doses above 75 mg is prudent. [15] The QTc prolongation risk at higher doses is more clinically significant in elderly patients with baseline cardiac disease.

Patients with renal impairment. No dose adjustment is required for mild to moderate renal impairment. Severe renal impairment (eGFR <30 mL/min/1.73 m2) warrants caution given reduced drug clearance, though published guidance does not specify an alternate dosing ceiling. [1]

Patients with hepatic impairment. Trazodone is extensively metabolized by CYP3A4 in the liver. Clinically significant hepatic impairment slows clearance and may increase sedation and adverse effects; starting at 25 mg and titrating slowly is appropriate. [1]

Pregnancy. Trazodone is FDA Pregnancy Category C (pre-2015 labeling) and the updated prescribing information notes insufficient human data to establish safety. Use during pregnancy should be reserved for cases where the benefit clearly outweighs risk, as assessed by the treating clinician in consultation with obstetrics. [1]

Drug Interactions That Affect Trazodone Sleep Dosing

Several drug interactions are clinically relevant at sleep doses, not just at antidepressant doses.

CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) increase trazodone plasma levels by reducing metabolism. A pharmacokinetic study found that ketoconazole 200 mg twice daily increased trazodone AUC by approximately 153%. [16] When these agents are co-prescribed, reducing the trazodone sleep dose by 50% is reasonable.

MAO inhibitors. Combining trazodone with any monoamine oxidase inhibitor carries risk of serotonin syndrome. The FDA label requires a 14-day washout after stopping an MAOI before starting trazodone, and vice versa. [1]

Other serotonergic agents. SSRIs, SNRIs, linezolid, and tramadol combined with trazodone may increase serotonin syndrome risk, especially at higher doses. At 50 mg sleep doses, the absolute serotonergic contribution of trazodone is low, but clinicians should document the combination and monitor for symptoms. [17]

CNS depressants. Alcohol and other sedating agents additive-sedate with trazodone. Patients should be counseled to avoid alcohol within four hours of their trazodone dose. [1]

Common and Serious Side Effects at Sleep Doses

The side-effect profile at 25 to 150 mg for sleep differs from the profile at antidepressant doses. At low doses, the most common adverse effects are next-day sedation, dry mouth, dizziness, and orthostatic hypotension. In the 2017 randomized trial (N=137), next-day sedation occurred in 14% of the trazodone 50 mg group versus 8% of placebo, a difference that was not statistically significant (P<0.08). [6]

Priapism is the rare but serious adverse effect most associated with trazodone. The estimated incidence is 1 in 6,000 to 1 in 10,000 male patients based on post-marketing surveillance data. [1] It can occur at any dose. Patients should be instructed to seek emergency care immediately for an erection lasting more than two to four hours, as ischemic priapism within six hours has a high rate of resolution without surgical intervention, while delays beyond 24 hours carry significant risk of erectile dysfunction. [18]

QTc prolongation. A pharmacovigilance analysis of FDA Adverse Event Reporting System (FAERS) data found trazodone associated with QT prolongation signals, with the strongest association at doses exceeding 200 mg per day. [19] At sleep doses of 50 to 100 mg, the QTc risk is low for patients without baseline cardiac disease or concurrent QT-prolonging medications.

Cognitive Behavioral Therapy for Insomnia First, Then Trazodone

Trazodone is not a first-line treatment for chronic insomnia. The AASM 2021 position statement reaffirms CBT-I as the recommended first-line treatment for chronic insomnia disorder, superior to pharmacotherapy in long-term outcomes. [20] CBT-I produces durable improvements in sleep-onset latency and sleep efficiency that persist after treatment ends, while drug effects generally require ongoing use.

A practical decision framework for trazodone use in insomnia:

1. Confirm the insomnia diagnosis and rule out primary sleep disorders (obstructive sleep apnea, restless legs syndrome) before prescribing any sedating drug.
2. Offer CBT-I or a structured sleep hygiene program as the initial intervention. Several digital CBT-I programs (Sleepio, Somryst) are available and FDA-cleared as prescription digital therapeutics. [21]
3. If pharmacotherapy is indicated after CBT-I failure or while awaiting CBT-I access, trazodone at 50 mg is a reasonable choice for patients who also have comorbid depression, anxiety, or a history of substance use disorder where scheduled agents are contraindicated.
4. Reassess every four to eight weeks. If insomnia persists at 150 mg, consider referral to a sleep medicine specialist rather than exceeding the off-label ceiling.

As the AASM Clinical Practice Guideline states directly: "We suggest that clinicians use CBT-I as the initial treatment for chronic insomnia disorder in adults." [7] Pharmacotherapy, including trazodone, is positioned as adjunctive or alternative when behavioral therapy is insufficient or inaccessible.

Stopping Trazodone: Tapering and Discontinuation

Trazodone is not physically addictive in the way benzodiazepines and Z-drugs are, but abrupt discontinuation after prolonged use at higher doses can cause discontinuation syndrome, including irritability, anxiety, dizziness, and rebound insomnia. [1]

For patients who have used trazodone at 100 to 150 mg nightly for more than four weeks, a gradual taper over two to four weeks is a reasonable approach. A common strategy is to reduce the dose by 25 mg every five to seven days. For patients on 50 mg, abrupt discontinuation is generally well tolerated, though a one-step reduction to 25 mg for one week before stopping is low-risk and may reduce rebound insomnia. [4]

Rebound insomnia after trazodone discontinuation appears to be milder than that observed with Z-drugs. A comparative pharmacology review in Current Psychiatry Reports noted that rebound insomnia intensity correlated with GABA-A receptor agonist activity, which trazodone lacks, supporting a gentler discontinuation profile. [22]

Monitoring Parameters After Starting Trazodone for Sleep

After initiating trazodone at any sleep dose, these parameters should be checked:

Blood pressure. Orthostatic hypotension can develop at the first dose and may persist. Checking supine and standing blood pressure at the first follow-up (one to two weeks) identifies patients at fall risk, particularly the elderly. [15]

Daytime function. Subjective daytime sedation, cognitive complaints, or driving concerns at follow-up are indications to reduce the dose or switch agents. If next-day sedation persists at 25 mg, trazodone may not be appropriate for that patient.

Cardiac history. For patients on multiple QT-prolonging agents or with a known prolonged QTc at baseline, an ECG before increasing above 100 mg at bedtime is prudent, though no published guideline mandates a specific threshold for ECG monitoring at sleep doses. [19]

Sleep diary or validated questionnaire. The Insomnia Severity Index (ISI) is a validated, freely available seven-item questionnaire that takes under three minutes to complete and tracks response over time. A reduction of six or more points on the ISI from baseline represents a clinically meaningful response. [23]